written by reader CFRX – just announcing OK results for Phase I

By maddogdne, September 18, 2016

Hello all –
Just hoping to perhaps draw Dr. KSS out regarding his view of this company. They are working on using lysins from bacteriophage as antibiotic compounds. Lysins are complex proteins, which I presume they are producing by recombinant DNA tech, but the exquisite specificity of the phage is lost when just the lysin is created. So insofar as I can find, these lysins are entirely nonspecific in their attack on bacterial cell walls, so they will likely have as big a negative impact on our microbiome as they do on the pathogens. I would be a strong supporter of anyone attempting to develop ultra-narrow-spectrum antibiotic compounds with high specificity for pathogens, but another broad spectrum antibiotic compound I think we don’t need, as it will lay waste our pivotally-important natural microbiome in the process of hitting the pathogen(s), thus providing few real new advantages.

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.

Share your thoughts...

1 Comment threads
0 Thread replies
Most reacted comment
Hottest comment thread
1 Comment authors
SoGiAm Recent comment authors

This site uses Akismet to reduce spam. Learn how your comment data is processed.


$CFRX np – you are on target maddogdne…junk, nonsense. http://www.stockgumshoe.com/2015/01/the-long-case-for-receptos/#comment-4198855